Table 1 Patient characteristics of the study cohorts at baseline
From: Implementation of a national AI technology program on cardiovascular outcomes and the health system
FFR-CT unavailable | FFR-CT available | P value | |
|---|---|---|---|
n (%) | n (%) | ||
35,688 (39.4) | 54,865 (60.6) | ||
Demographics | |||
Age at index CT scan (years) | 58 (49, 67) | 59 (50, 68) | <0.0001 |
Female | 17,141 (48.0)a | 26,393 (48.2)a | 0.59 |
Type 1 diabetes mellitus | 454 (1.3) | 707 (1.3) | 0.84 |
Type 2 diabetes mellitus | 4,869 (13.6) | 7,516 (13.7) | 0.82 |
Hyperlipidemia | 8,397 (23.5) | 12,724 (23.2) | 0.24 |
Hypertension | 14,788 (41.4) | 21,905 (39.9) | <0.0001 |
Angina | 6,457 (18.1) | 9,843 (17.9) | 0.57 |
Myocardial Iifarction | 1,597 (4.5) | 2,355 (4.3) | 0.19 |
Valve disorder | 3,667 (10.3) | 4,890 (7.9) | 0.03 |
Heart failure | 4,014 (11.2) | 5,362 (9.8) | <0.0001 |
TIA | 341 (1.0) | 454 (0.8) | 0.048 |
Cerebral infarction | 681 (1.9) | 952 (1.7) | 0.06 |
Atherosclerosis | 520 (1.5) | 788 (1.4) | 0.79 |
Aortic aneurysm | 1,015 (2.8) | 1,475 (2.7) | 0.16 |
COPD | 3,597 (10.1) | 4,401 (9.3) | 0.0038 |
Kidney disease | 2,556 (7.2) | 3,496 (6.4) | <0.001 |
Medicationsb | n = 34,554 | n = 51,602 | |
ACE inhibitors | 7,635 (22.1) | 11,502 (22.3) | 0.50 |
Antiplatelets | 10,282 (29.8) | 15,592 (30.2) | 0.15 |
Beta blockers | 10,313 (29.9) | 16,066 (31.1) | <0.0001 |
Calcium channel blockers | 6,239 (18.1) | 9,887 (19.2) | <0.0001 |
Statins | 16,960 (49.1) | 26,434 (51.2) | <0.0001 |
Vitamin K antagonist | 1,096 (3.2) | 1,167 (2.3) | <0.0001 |
Factor Xa | 2,794 (8.1) | 4,723 (9.2) | <0.0001 |
Lipid-lowering medications | 699 (2.0) | 1,266 (2.5) | <0.0001 |
